Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence of benzhydrocodone/paracetamol (KP 201) versus hydrocodone/paracetamol (Norco) in volunteers

Next Previous
Trial Profile

Bioequivalence of benzhydrocodone/paracetamol (KP 201) versus hydrocodone/paracetamol (Norco) in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benzhydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
  • Indications Acute pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors KemPharm; Zevra Therapeutics

Most Recent Events

  • 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
  • 05 May 2016 According to a KemPharm media release, the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US FDA voted in favor of approval for benzhydrocodone/paracetamol hydrochloride combination (Apadaz) for the management of acute pain that requires opioid and voted against inclusion of abuse deterrent labeling for the product.
  • 10 Mar 2016 According to a KemPharm media release, the company has submitted an NDA under the 505(b)(2) regulatory pathway to the US FDA. The FDA has accepted the NDA, granted priority review and assigned a PDUFA date of June 9, 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top